DE69909998D1 - Antagoniste der arylkohlenwasserstoff-rezeptoren liganden - Google Patents

Antagoniste der arylkohlenwasserstoff-rezeptoren liganden

Info

Publication number
DE69909998D1
DE69909998D1 DE69909998T DE69909998T DE69909998D1 DE 69909998 D1 DE69909998 D1 DE 69909998D1 DE 69909998 T DE69909998 T DE 69909998T DE 69909998 T DE69909998 T DE 69909998T DE 69909998 D1 DE69909998 D1 DE 69909998D1
Authority
DE
Germany
Prior art keywords
antagoniste
aryl carbon
receptors ligands
ligands
arylhydrocarbon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69909998T
Other languages
English (en)
Other versions
DE69909998T2 (de
Inventor
Jean-Francois Savouret
Robert-Frederic Casper
Edwin Milgrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CASPER, ROBERT-FREDERIC, TORONTO, ONTARIO, CA
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of DE69909998D1 publication Critical patent/DE69909998D1/de
Application granted granted Critical
Publication of DE69909998T2 publication Critical patent/DE69909998T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
DE69909998T 1998-05-05 1999-05-05 ANTAGONISTE DER LIGANDEN des Arylkohlenwasserstoff-Rezeptors Expired - Fee Related DE69909998T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9805673A FR2778337B1 (fr) 1998-05-05 1998-05-05 Antagonistes des ligands du recepteur des arylhydrocarbures
FR9805673 1998-05-05
PCT/FR1999/001063 WO1999056737A1 (fr) 1998-05-05 1999-05-05 Antagonistes des ligands du recepteur des arylhydrocarbures

Publications (2)

Publication Number Publication Date
DE69909998D1 true DE69909998D1 (de) 2003-09-04
DE69909998T2 DE69909998T2 (de) 2004-04-22

Family

ID=9526044

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69909998T Expired - Fee Related DE69909998T2 (de) 1998-05-05 1999-05-05 ANTAGONISTE DER LIGANDEN des Arylkohlenwasserstoff-Rezeptors

Country Status (9)

Country Link
EP (1) EP1075256B1 (de)
JP (1) JP2002513754A (de)
AT (1) ATE245973T1 (de)
AU (1) AU3528299A (de)
CA (1) CA2331364A1 (de)
DE (1) DE69909998T2 (de)
ES (1) ES2205807T3 (de)
FR (1) FR2778337B1 (de)
WO (1) WO1999056737A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038620A2 (en) * 1998-12-24 2000-07-06 1333366 Ontario Inc. A composition useful to treat periodontal disease
US6716883B1 (en) 1998-12-24 2004-04-06 1333366 Ontario Inc. Composition useful to treat periodontal disease
DE60030845T2 (de) * 1999-01-29 2007-05-03 Sunstar Inc., Takatsuki Arzneimittel, lebensmittel und orale zusammensetzungen die stilben-artige verbindungen enthalten
AU778767C (en) * 1999-05-18 2006-09-07 Theracos, Inc. Novel diphenylethylene compounds
PE20010540A1 (es) * 1999-07-30 2001-05-15 Procter & Gamble Composicion de fitoalexinas estilbenicas util para la profilaxis y tratamiento de sintomas asociados con el resfriado y enfermedades similares a la influenza
US7323496B2 (en) 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US6472436B1 (en) * 2000-07-17 2002-10-29 The Salk Institute For Biological Studies Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
US6410596B1 (en) * 2000-08-16 2002-06-25 Insmed Incorporated Compositions containing hypoglycemically active stillbenoids
US6552085B2 (en) * 2000-08-16 2003-04-22 Insmed Incorporated Compositions containing hypoglycemically active stilbenoids
US6541522B2 (en) 2000-08-16 2003-04-01 Insmed Incorporated Methods of using compositions containing hypotriglyceridemically active stilbenoids
FR2816843B1 (fr) * 2000-11-23 2006-10-27 Actichem Inhibiteurs de l'enzyme 5 alpha-reductase
KR100836207B1 (ko) * 2001-01-18 2008-06-09 웰리켐 바이오 테크 인크. 면역 질환 치료용의 신규한 1,2-디페닐에텐 유도체
CN1398838A (zh) * 2001-07-26 2003-02-26 中国人民解放军军事医学科学院放射医学研究所 二苯乙烯类化合物制备以及它们在治疗和预防糖尿病中的应用
WO2003039557A1 (en) * 2001-11-02 2003-05-15 The Regents Of The University Of California Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection
FR2844715B1 (fr) * 2002-09-20 2007-04-27 Af Consulting Composition pour des soins de la peau, et contenant un ou des oligomeres de resveratrol, en particulier de l'epsilone-viniferine, et ou certains de leurs derives
ITRM20020562A1 (it) * 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
EP1418164A1 (de) * 2002-11-07 2004-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Neue Stilbenderivate und deren Verwendung als Antagonisten der aryl hydrocarbon receptor Liganden
WO2004077058A1 (en) * 2003-02-26 2004-09-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with aryl hydrocarbon receptor (ahr)
WO2006019841A2 (en) * 2004-07-13 2006-02-23 Government Of The United States Of America Treatment of viral infections with egr 1 activators
CN1723884A (zh) * 2004-07-21 2006-01-25 中国人民解放军军事医学科学院放射医学研究所 顺式－1，2－取代的二苯乙烯衍生物用于制备治疗或预防糖尿病的药物的用途
DE102005005274A1 (de) * 2005-02-04 2006-08-10 Peter Heger Verwendung von Hydroxystilben-haltigen Wirkstoffen zur Prävention und Behandlung chronisch-entzündlicher Erkrankungen
DE102005056890A1 (de) 2005-11-28 2007-05-31 Institut für Umweltmedizinische Forschung gGmbH Kosmetisches Verfahren zur Beeinflussung der Melaninbildung in der Haut
US7855310B2 (en) 2006-05-03 2010-12-21 Symrise Gmbh & Co. Kg AH receptor antagonists
FR2942409B1 (fr) * 2009-02-20 2013-07-26 Natacha Voillot Composition pharmaceutique pour la prevention des avortements a repetition.
WO2010095926A1 (en) * 2009-02-20 2010-08-26 N.V. Nutricia Use of reveratrol for preserving cognitive functioning
TW201141536A (en) 2009-12-21 2011-12-01 Colgate Palmolive Co Oral care compositions and methods
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
AU2017235461B2 (en) 2016-03-15 2023-02-23 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
CN107510694B (zh) * 2016-06-16 2022-03-29 中国科学院上海巴斯德研究所 激活潜伏感染的艾滋病病毒的化合物及其在艾滋病治疗中的应用
CN109288823A (zh) * 2018-10-12 2019-02-01 中国疾病预防控制中心病毒病预防控制所 白皮杉醇在制备治疗朊病毒引起疾病药物中的用途
WO2022065910A1 (ko) 2020-09-25 2022-03-31 씨제이제일제당 (주) 스틸벤계 화합물을 포함하는 항콕시듐증 조성물 및 이의 용도
KR102394378B1 (ko) * 2020-10-14 2022-05-03 한림대학교 산학협력단 피부 각질세포에서의 아릴탄화수소 수용체 억제자(AhRR) 과발현 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6711158A (de) * 1966-08-17 1968-02-19
JPS61171427A (ja) * 1985-01-24 1986-08-02 Osaka Chem Lab 血栓等予防物質
JP2562092B2 (ja) * 1992-03-05 1996-12-11 ユシロ化学工業株式会社 変異原抑制剤
JPH0753359A (ja) * 1993-06-11 1995-02-28 Kao Corp リポキシゲナーゼ阻害剤
JPH08175960A (ja) * 1994-12-27 1996-07-09 Kao Corp シワ予防用化粧料
CN1065411C (zh) * 1995-06-18 2001-05-09 侯润安 新型保健营养奶粉及其生产方法
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
JP3053368B2 (ja) * 1996-06-06 2000-06-19 ユシロ化学工業株式会社 化粧料及びその製造方法
US6270780B1 (en) * 1997-07-25 2001-08-07 Chesebrough-Pond's Usa Co., Division Of Conopco Cosmetic compositions containing resveratrol

Also Published As

Publication number Publication date
FR2778337A1 (fr) 1999-11-12
EP1075256A1 (de) 2001-02-14
JP2002513754A (ja) 2002-05-14
ES2205807T3 (es) 2004-05-01
EP1075256B1 (de) 2003-07-30
AU3528299A (en) 1999-11-23
ATE245973T1 (de) 2003-08-15
WO1999056737A1 (fr) 1999-11-11
CA2331364A1 (fr) 1999-11-11
FR2778337B1 (fr) 2001-08-31
DE69909998T2 (de) 2004-04-22

Similar Documents

Publication Publication Date Title
DE69909998D1 (de) Antagoniste der arylkohlenwasserstoff-rezeptoren liganden
FI980122A0 (fi) Loesliga lymfotoxin- -receptorer och anti-lymfotoxinreceptor och ligandantikroppar som terapeutiska medel foer behandling av immunologisk sjukdom
ES2108120T3 (es) Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
DE69133156D1 (de) Behandlung von gemütskrankheiten mit funktionellen antagonisten des glycin/nmda-rezeptorkomplexes
DE69532687D1 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung der ulzerativen kolitis
BG105711A (en) 3-azabicyclo[3.1.0]hexane derivatives as opiate receptors ligands
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
NO20000521D0 (no) 1-(N-fenylaminoalkyl)-piperazin derivater substituert i posisjon 2 på fenylringen
NO20015413L (no) Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser
DK0840732T3 (da) Substituerede benzolactamforbindelser som substans P-antagonister
ATE276770T1 (de) Dopamin und serotonin transport-ligande und bilderzeugungsmitteln
ATE171447T1 (de) Benzimidazole derivate
DE69107487D1 (de) Installation zum kontinuierlichen Trocknen, Dehydratisieren oder Kochen mittels Mikrowellen von körnigen oder pulverförmigen Produkten.
ATE255129T1 (de) Hemmer von apoptose
DK0900200T5 (da) Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet
ATE315392T1 (de) Zusammensetzungen zur behandlung chronischer lymphatischer leukämie
DE69819903D1 (de) Bizyklische verbindungen als liganden der 5-ht1 rezeptoren
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
AR033957A1 (es) Nuevos compuestos
WO2004055513A3 (en) Use of cd137 antagonists for the treatment of tumors
MY133390A (en) Azabicyclic 5ht1 receptor ligands
ATE227262T1 (de) Perfluor-n-alkansulfonsäure-derivate
NO20014961L (no) Integrin-reseptor-ligander
ATE289995T1 (de) Thiazol-derivate als ppar-gamma-ligande
ATE469887T1 (de) Substituierte heterocyclische verbindungen und deren verwendung zur behandlung multipler medikamentenresistenz

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M

Owner name: CASPER, ROBERT-FREDERIC, TORONTO, ONTARIO, CA

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee